Clinical Trials Logo

Clinical Trial Summary

This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05481658
Study type Interventional
Source Icahn School of Medicine at Mount Sinai
Contact Vicky K Wong, MS, CCRC
Phone 212-241-3288
Email vicky.wong@mssm.edu
Status Recruiting
Phase Phase 1
Start date October 6, 2022
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT01941901 - Calcium Electroporation for Treatment of Cutaneous Metastases Phase 2